« Back to Record
Citation APA

Di Leo, A., Desmedt, C., Bartlett, J. M. S., Piette, F., Ejlertsen, B., Pritchard, K., Larsimont, D., Poole, C., Isola, J., Earl, H., Mouridsen, H., O'Malley, F. P., Cardoso, F., Tanner, M., Munro, A., Twelves, C. J., Sotiriou, C., Shepherd, L., Cameron, D. A., Piccart-Gebhart, M., Buyse, M., & HER2/TOP2A Meta-analysis Study Group, (2011). HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet oncology, 12(12), 1134-1142. doi:10.1016/S1470-2045(11)70231-5


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/113274

Di Leo, A., Desmedt, C., Bartlett, J. M. S., Piette, F., Ejlertsen, B., Pritchard, K., Larsimont, D., Poole, C., Isola, J., Earl, H., Mouridsen, H., O'Malley, F. P., Cardoso, F., Tanner, M., Munro, A., Twelves, C. J., Sotiriou, C., Shepherd, L., Cameron, D. A., Piccart-Gebhart, M., Buyse, M., & HER2/TOP2A Meta-analysis Study Group, (2011). HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet oncology, 12(12), 1134-1142. doi:10.1016/S1470-2045(11)70231-5